Search results
View the profiles of people named Ben OLeary. Join Facebook to connect with Ben OLeary and others you may know. Facebook gives people the power to share...
Abstract. CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence from clinical samples.
17 de jun. de 2020 · Ben O’Leary, Rosalind J Cutts, Xin Huang, Sarah Hrebien, Yuan Liu, Fabrice André, Sibylle Loibl, Sherene Loi, Isaac Garcia-Murillas, Massimo Cristofanilli, Cynthia Huang Bartlett, Nicholas C Turner, Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer, JNCI: Journal of ...
23 de feb. de 2024 · Dr Ben O'Leary is an NIHR Academic Clinical Lecturer in Molecular Oncology who is researching the evolution of resistance to cancer therapies at the ICR. Ben O'Leary is a Clinician Scientist at the ICR and an Honorary Consultant in Clinical Oncology at The Royal Marsden hospital, working in the Molecular Oncology group.
Dr Ben O’Leary. Clinician Scientist and Honorary Consultant in Clinical Oncology MA Cantab, MBBS, MSc, MRCP, FRCR, PhD. Specialism: Head and neck. Available at: Chelsea. Special interests. Head and neck cancer. Clinical trials. Translational research. Liquid biopsies. Cancer evolution. Novel therapies. Biography.
Benjamin O'Leary is a patient who had a brain tumor that caused him to say whatever he was thinking. Benjamin had been diagnosed with with a brain tumor. The tumor was pressing on his frontal lobe, causing him to say everything he thought. He had to be told directly that he was being rude...
Home. Our Research. Researchers and groups. Dr Ben O'Leary. Publications Highlights View all by category. Types of Publications. Journals. Journal Articles. O'Leary, B. (2023). PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching. Nat rev clin oncol, Vol.20 (2), pp. 67-68.
